A system of reverse genetics was used to generate influenza A/H1N1 viruses harbouring neuraminidase (NA) mutations previously associated with resistance to NA inhibitors in various viral subtypes. The His274Tyr and Glu119Gln mutants were rescued whereas the Arg292Lys and Glu119→Gly, Val, Ala or Asp mutants could not be generated. In NA inhibition assays, the His274Tyr mutant was resistant to oseltamivir (430-fold over wild-type) and BCX-1812 (50-fold) but was sensitive to zanamivir. A similar trend was seen when the mutant was evaluated by plaque reduction assay (PRA). The Glu119Gln mutant expressed a low level of resistance to oseltamivir (ninefold) and zanamivir (fourfold) in NA inhibition assay but was only marginally resistant to oseltamivir (fourfold) in PRA. The replication capacity of both mutants, in particular that of the His274Tyr virus, was impaired when compared with the wild-type virus in vitro.
References
1.
PaleseP., TobitaM., UedaM., & CompansR.Characterization of temperature-sensitive influenza virus defective in neuraminidase.Virology1974; 61: 397–410.
2.
ColmanP.M., HoyneP.A., & LawrenceM.C.Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase.Journal of Virology1993; 67: 2972–2980.
Von ItzsteinM., WuW.Y., KokG.B., PeggM.S., DyasonJ.C., JinB., Van PhanT., SmytheM.L., WhiteH.F., & OliverS.W.Rational design of potent sialidase-based inhibitors of influenza virus replication.Nature1993; 363: 418–423.
5.
LiW., EscarpeP.A., EisenbergE.J., CundyK.C., SweetC., JakemanK.J., MersonJ., LewW., WilliamsM., ZhangL., KimC.U., BischofbergerN., ChenM.S., & MendelD.B.Identification of GS 4104 as an orally bioavailable prodrug of the influenza neuraminidase inhibitor GS 4071.Antimicrobial Agents & Chemotherapy1998; 42: 647–653.
6.
McKimm-BreschkinJ.L.Neuraminidase inhibitors for the treatment and prevention of influenza.Expert Opinion on Pharmacotherapy2002; 3: 103–112.
7.
BabuY.S., ChandP., BantiaS., KotianP., DehghaniA., El-KattanY., LinT.H., HutchisonT.L., ElliottA.J., ParkerC.D., AnanthS.L., HornL.L., LaverG.W., & MontgomeryJ.A.BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.Journal of Medicinal Chemistry2000; 19: 3482–3486.
8.
KatiW.M., MontgomeryD., CarrickR., GubarevaL., MaringC., McDanielK., StefyK., MollaA., HaydenF.G., KempfD., & KohlbrennerW.In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.Antimicrobial Agents & Chemotherapy2002; 46: 1014–1021.
9.
GubarevaL.V., BethellR.C., HartG.J., MurtiK.G., PennC.R., & WebsterR.G.Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.Journal of Virology1996; 70: 1818–1827.
10.
McKimm-BreschkinJ.L., SahasrabudheA., BlickT.J., McDonaldM., ColmanP.M., HartG.J., BethellR.C., & VargheseJ.N.Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.Journal of Virology1998; 72: 2456–2462.
11.
TaiC.Y., EscarpeP.A., SidwellR.W., WilliamsM.A., LewW., WuH., KimC.U., & MendelD.B.Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.Antimicrobial Agents & Chemotherapy1998; 42: 3234–3241.
12.
MollaA., KatiW., CarrickR., StefyK., ShiY., MontgomeryD., GusickN., StollV.S., StewartK.D., NgT.I., MaringC., KempfD., & KohlbrennerW.In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.Journal of Virology2002; 76: 5380–5386.
13.
WhitleyR.J., HaydenF.G., ReisingerK.S., YoungN., DutkowskiR., IpeD., MillsR.G., & WardP.Oral oseltamivir treatment of influenza in children.Pediatric Infectious Diseases Journal2001; 20: 127–133.
14.
GubarevaL.V., RobinsonM.J., BethellR.C., & WebsterR.G.Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.Journal of Virology1997; 71: 3385–3390.
15.
BarnettJ.M., CadmanA., BurrellF.M., MadarS.H., LewisA.P., TisdaleM., & BethellR.C.In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.Virology1999; 20: 286–295.
16.
BlickT.J., TiongT., SahasrabudheA., VargheseJ.N., ColmanP.M., HartG.J., BethellR.C., & McKimm-BreschkinJ.L.Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.Virology1995; 20: 475–484.
17.
StaschkeK.A., ColacinoJ.M., BaxterA.J., AirG.M., BansalA., HornbackW.J., MunroeJ.E., & LaverW.G.Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.Virology1995; 214: 642–646.
18.
GotoH., BethellR.C., & KawaokaY.Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.Virology1997; 238: 265–272.
19.
WangM.Z., TaiC.Y., & MendelD.B.Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir.Antimicrobial Agents & Chemotherapy2002; 46: 3809–3816.
20.
GubarevaL.V., KaiserL., MatrosovichM.N., Soo-HooY., & HaydenF.G.Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.Journal of Infectious Diseases2001; 183: 523–531.
21.
WeinstockD.M., GubarevaL.V., & ZucottiG.Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient.New England Journal of Medicine2003; 348: 867–868.
22.
FodorE., DevenishL., EngelhardtO.G., PaleseP., BrownleeG.G., & Garcia-SastreA.Rescue of influenza A virus from recombinant DNA.Journal of Virology1999; 73: 9679–9682.
23.
PotierM., MameliL., BelisleM., DallaireL., & MelanconS.B.Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.Annals of Biochemistry1979; 94: 287–296.
24.
HaydenF.G., CoteK.M., & DouglasR.G.Jr.. Plaque inhibition assay for drug susceptibility testing of influenza viruses.Antimicrobial Agents & Chemotherapy1980; 17: 865–870.
25.
GubarevaL.V., WebsterR.G., & HaydenF.G.Comparison of the activities of zanamivir, oseltamivir and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Antimicrobial Agents & Chemotherapy2001; 45: 3403–3408.
26.
TisdaleM.Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors.Review in Medical Virology2000; 10: 45–55.
27.
WhetherallN.T., TrivediT., ZellerJ., Hodges-SavolaC., McKimm-BreshkinJ.L., ZambonM., & HaydenF.G.Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.Journal of Clinical Microbiology2003; 41: 742–750.
28.
IvesJ.A.L., CarrJ.A., MendelD.B., TaiC.Y., LambkinR., KellyL., OxfordJ.S., HaydenF.G., & RobertsN.A.The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo.Antiviral Research2002; 55: 307–317.
